Next generation organ-on-a-chip (OOC) technology to be used to investigate the human gut microbiome for improving outcomes for patients with liver
CN Bio FDA collaboration expanded
The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications Extension aims to
Introducing the PhysioMimix® OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ
CN Bio’s PhysioMimix® technology receives FDA recognition
FDA publication demonstrates advantages of PhysioMimix® in drug safety and metabolism applications, over standard techniques Represents the first
CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following
CN Bio to provide drug metabolism and safety toxicity testing services
Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell
CN Bio and Imperial College London Collaboration
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis. CN Bio’s Liver-on-Chip technology to define
CN Bio makes key senior appointments to support international commercial development
Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales Cambridge, UK, 05 August 2020: CN Bio, a leading